Literature DB >> 32074316

Antibiotic Practice Patterns for Extremity Wound Infections among Blast-Injured Subjects.

Laveta Stewart1,2, Ping Li1,2, Maj Dana M Blyth3, Wesley R Campbell4, Joseph L Petfield5, Margot Krauss6, Lauren Greenberg6, David R Tribble1.   

Abstract

INTRODUCTION: We examined antibiotic management of combat-related extremity wound infections (CEWI) among wounded U.S. military personnel (2009-2012).
METHODS: Patients were included if they sustained blast injuries, resulting in ≥1 open extremity wound, were admitted to participating U.S. hospitals, developed a CEWI (osteomyelitis or deep soft-tissue infections) within 30 days post-injury, and received ≥3 days of relevant antibiotic (s) for treatment.
RESULTS: Among 267 patients, 133 (50%) had only a CEWI, while 134 (50%) had a CEWI plus concomitant non-extremity infection. In the pre-diagnosis period (4-10 days prior to CEWI diagnosis), 95 (36%) patients started a new antibiotic with 28% of patients receiving ≥2 antibiotics. During CEWI diagnosis week (±3 days of diagnosis), 209 (78%) patients started a new antibiotic (71% with ≥2 antibiotics). In the week following diagnosis (4-10 days after CEWI diagnosis), 121 (45%) patients started a new antibiotic with 39% receiving ≥2 antibiotics. Restricting to ±7 days of CEWI diagnosis, patients commonly received two (35%) or three (27%) antibiotics with frequent combinations involving carbapenem, vancomycin, and fluoroquinolones.
CONCLUSIONS: Substantial variation in antibiotic prescribing patterns related to CEWIs warrants development of combat-related clinical practice guidelines beyond infection prevention, to include strategies to reduce the use of unnecessary antibiotics and improve stewardship. Published by Oxford University Press on behalf of Association of Military Surgeons of the United States 2020.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32074316      PMCID: PMC7041850          DOI: 10.1093/milmed/usz211

Source DB:  PubMed          Journal:  Mil Med        ISSN: 0026-4075            Impact factor:   1.437


  29 in total

1.  Guidelines for the prevention of infection after combat-related injuries.

Authors:  Duane R Hospenthal; Clinton K Murray; Romney C Andersen; Jeffrey P Blice; Jason H Calhoun; Leopoldo C Cancio; Kevin K Chung; Nicholas G Conger; Helen K Crouch; Laurie C D'Avignon; James R Dunne; James R Ficke; Robert G Hale; David K Hayes; Erwin F Hirsch; Joseph R Hsu; Donald H Jenkins; John J Keeling; R Russell Martin; Leon E Moores; Kyle Petersen; Jeffrey R Saffle; Joseph S Solomkin; Sybil A Tasker; Alex B Valadka; Andrew R Wiesen; Glenn W Wortmann; John B Holcomb
Journal:  J Trauma       Date:  2008-03

Review 2.  Prevention of infections associated with combat-related extremity injuries.

Authors:  Clinton K Murray; William T Obremskey; Joseph R Hsu; Romney C Andersen; Jason H Calhoun; Jon C Clasper; Timothy J Whitman; Thomas K Curry; Mark E Fleming; Joseph C Wenke; James R Ficke
Journal:  J Trauma       Date:  2011-08

Review 3.  Guidelines for the prevention of infections associated with combat-related injuries: 2011 update: endorsed by the Infectious Diseases Society of America and the Surgical Infection Society.

Authors:  Duane R Hospenthal; Clinton K Murray; Romney C Andersen; R Bryan Bell; Jason H Calhoun; Leopoldo C Cancio; John M Cho; Kevin K Chung; Jon C Clasper; Marcus H Colyer; Nicholas G Conger; George P Costanzo; Helen K Crouch; Thomas K Curry; Laurie C D'Avignon; Warren C Dorlac; James R Dunne; Brian J Eastridge; James R Ficke; Mark E Fleming; Michael A Forgione; Andrew D Green; Robert G Hale; David K Hayes; John B Holcomb; Joseph R Hsu; Kent E Kester; Gregory J Martin; Leon E Moores; William T Obremskey; Kyle Petersen; Evan M Renz; Jeffrey R Saffle; Joseph S Solomkin; Deena E Sutter; David R Tribble; Joseph C Wenke; Timothy J Whitman; Andrew R Wiesen; Glenn W Wortmann
Journal:  J Trauma       Date:  2011-08

4.  A Global Declaration on Appropriate Use of Antimicrobial Agents across the Surgical Pathway.

Authors: 
Journal:  Surg Infect (Larchmt)       Date:  2017 Nov/Dec       Impact factor: 2.150

5.  The nature and extent of war injuries sustained by combat specialty personnel killed and wounded in Afghanistan and Iraq, 2003-2011.

Authors:  Andrew J Schoenfeld; John C Dunn; Julia O Bader; Philip J Belmont
Journal:  J Trauma Acute Care Surg       Date:  2013-08       Impact factor: 3.313

6.  Variation in Postinjury Antibiotic Prophylaxis Patterns Over Five Years in a Combat Zone.

Authors:  Bradley A Lloyd; Clinton K Murray; William Bradley; Faraz Shaikh; Deepak Aggarwal; M Leigh Carson; David R Tribble
Journal:  Mil Med       Date:  2017-03       Impact factor: 1.437

7.  Early infectious outcomes after addition of fluoroquinolone or aminoglycoside to posttrauma antibiotic prophylaxis in combat-related open fracture injuries.

Authors:  Bradley A Lloyd; Clinton K Murray; Faraz Shaikh; M Leigh Carson; Dana M Blyth; Elizabeth R Schnaubelt; Timothy J Whitman; David R Tribble
Journal:  J Trauma Acute Care Surg       Date:  2017-11       Impact factor: 3.313

8.  Characterization of Lower Extremity Blast Injury.

Authors:  Claire E Webster; Jon Clasper; Daniel J Stinner; Joseph Eliahoo; Spyros D Masouros
Journal:  Mil Med       Date:  2018-09-01       Impact factor: 1.437

9.  Use of sterile pre-fabricated antibiotic beads in the combat hospital setting.

Authors:  Wade T Gordon; Michael G Petrides; Philip A Gunn; Michael Howard
Journal:  Mil Med       Date:  2013-03       Impact factor: 1.437

10.  Ten years at war: comprehensive analysis of amputation trends.

Authors:  Chad A Krueger; Joseph C Wenke; James R Ficke
Journal:  J Trauma Acute Care Surg       Date:  2012-12       Impact factor: 3.313

View more
  2 in total

Review 1.  IDCRP Combat-Related Extremity Wound Infection Research.

Authors:  Joseph L Petfield; Louis R Lewandowski; Laveta Stewart; Clinton K Murray; David R Tribble
Journal:  Mil Med       Date:  2022-05-04       Impact factor: 1.563

2.  IDCRP Trauma-Related Infection Research.

Authors:  David R Tribble
Journal:  Mil Med       Date:  2022-05-04       Impact factor: 1.563

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.